These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16004078)

  • 1. TSAO derivatives the first non-peptide inhibitors of HIV-1 RT dimerization.
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ
    Antivir Chem Chemother; 2005; 16(3):147-53. PubMed ID: 16004078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TSAO derivatives, inhibitors of HIV-1 reverse transcriptase dimerization: recent progress.
    Camarasa MJ; Velázquez S; San-Félix A; Pérez-Pérez MJ; Bonache MC; De Castro S
    Curr Pharm Des; 2006; 12(15):1895-907. PubMed ID: 16724955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase.
    Camarasa MJ; San-Félix A; Velázquez S; Pérez-Pérez MJ; Gago F; Balzarini J
    Curr Top Med Chem; 2004; 4(9):945-63. PubMed ID: 15134550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
    Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
    J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
    Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
    J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains.
    Lobatón E; Velázquez S; Pérez-Pérez MJ; Jimeno ML; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):707-10. PubMed ID: 11563097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
    Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
    Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present, and future perspectives.
    Campiani G; Ramunno A; Maga G; Nacci V; Fattorusso C; Catalanotti B; Morelli E; Novellino E
    Curr Pharm Des; 2002; 8(8):615-57. PubMed ID: 11945162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
    Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
    J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
    Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
    Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
    Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
    J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
    de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
    Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.
    Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Barrios FR; Gago F; Camarasa MJ; San-Félix A
    J Med Chem; 2005 Oct; 48(21):6653-60. PubMed ID: 16220981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of NNRTIs on HIV reverse transcriptase dimerization.
    Tachedjian G; Goff SP
    Curr Opin Investig Drugs; 2003 Aug; 4(8):966-73. PubMed ID: 14508881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential multifunctional inhibitors of HIV-1 reverse transcriptase. Novel [AZT]-[TSAO-T] and [d4T]-[TSAO-T] heterodimers modified in the linker and in the dideoxynucleoside region.
    Velázquez S; Tuñón V; Jimeno ML; Chamorro C; De Clercq E; Balzarini J; Camarasa MJ
    J Med Chem; 1999 Dec; 42(25):5188-96. PubMed ID: 10602704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unusual lability of 5'-O-tert-butyldimethylsilyl group on 4''-acyl TSAO derivatives.
    de Castro S; Pérez-Pérez MJ; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):959-61. PubMed ID: 14565321
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
    Balzarini J
    Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
    de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
    J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-3 substituted TSAO derivatives as a probe to explore the dimeric interface of HIV-1 reverse transcriptase.
    Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Camarasa MJ; San-Félix A
    Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):947-9. PubMed ID: 14565318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.